 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3637383940414243444546...208209» |
- ||| HR021618 / Jiangsu Hengrui Pharma
Trial completion: HR021618 in Moderate to Severe Pain After Abdominal Surgery (clinicaltrials.gov) - May 15, 2025
P2, N=60, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Allosteric regulation of UBIAD1 trafficking from ER to Golgi revealed by chemical genetic screening. (Pubmed Central) - May 15, 2025
Apatinib-mediated Golgi transport of UBIAD1 enhanced the ERAD of HMGCR. Photoaffinity labeling studies indicated that Apatinib binds directly to UBIAD1, suggesting that the drug allosterically activates GGpp-induced transport of UBIAD1 from the ER to the Golgi.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Safety and efficacy of apatinib in combination treatment versus apatinib as second-line treatment for advanced gastric cancer. (Pubmed Central) - May 15, 2025
In terms of safety, the primary adverse reactions included myelosuppression, elevated AST and ALT levels, hypertension, hand-foot syndrome, hyperbilirubinemia, proteinuria, fatigue, and vomiting, with a low incidence of grade 3-4 toxicities. Apatinib-based combination therapy significantly enhances both progression-free survival and overall survival in patients with advanced gastric cancer when compared to monotherapy, while also demonstrating a safe and reliable profile.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Journal: Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer. (Pubmed Central) - May 15, 2025
This study indicates that the combination of dalpiciclib and AI elicits comparable responses and demonstrates improved safety profiles when compared to NCT in patients with HR+ HER2 negative breast tumors. Furthermore, RCB and pCR may not serve as optimal endpoints for evaluating the efficacy of CDK4/6i-based NET.
- || SHR-1918 / Jiangsu Hengrui Pharma
Clinical, P2 data, Journal: Angiopoietin-Like 3 Antibody Therapy in (Pubmed Central) - May 15, 2025
P2
These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831).
- SHR-2004 / Jiangsu Hengrui Pharma
Pharmacokinetics and pharmacodynamics of SHR-2004, a novel humanized monoclonal antibody targeting factor XI, in patients with atrial fibrillation (Station 12(Research Gateway)) - May 15, 2025 - Abstract #ESCWCC2025ESC_WCC_6406;
Multiple subcutaneous doses of SHR-2004 were safe and well tolerated in patients with AF, particularly regarding the low risk of bleeding. The safety, PK, and PD data from this trial support further exploration of SHR-2004 in patients with AF.
- | New P2 trial: HER2-DM-NACT: This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. (clinicaltrials.gov) - May 14, 2025
P2, N=30, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 14, 2025
P2, N=40, Not yet recruiting, Sponsor: Anhui Provincial Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trial initiation date: Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC (clinicaltrials.gov) - May 14, 2025
P2, N=164, Not yet recruiting, Sponsor: Zhigang Li
The safety, PK, and PD data from this trial support further exploration of SHR-2004 in patients with AF. Initiation date: Mar 2025 --> Jul 2025
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial: PARTOM: Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC (clinicaltrials.gov) - May 14, 2025
P2, N=40, Recruiting, Sponsor: Jianbin Bi
- || HRS-9821 / Jiangsu Hengrui Pharma
Enrollment closed: Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients (clinicaltrials.gov) - May 14, 2025
P1, N=106, Active, not recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Initiation date: Mar 2025 --> Jul 2025 Recruiting --> Active, not recruiting
- || SHR7280 / Jiangsu Hengrui Pharma
New P1 trial: A Trial of SHR7280 in Healthy Subjects (clinicaltrials.gov) - May 14, 2025
P1, N=16, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial, Circulating tumor DNA: DNADalHR: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov) - May 14, 2025
P2, N=393, Not yet recruiting, Sponsor: Peking University People's Hospital
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov) - May 14, 2025
P2, N=132, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Jan 2025
- || Clinical, Retrospective data, Review, Journal, Checkpoint inhibition: Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials. (Pubmed Central) - May 14, 2025
The general safety of ICIs ranked from high to low for grade 1-5 anemia were as follows: avelumab, nivolumab, pembrolizumab, sintilimab, camrelizumab, and tislelizumab...Taking ICI monotherapy, nivolumab plus ipilimumab were generally safer than taking chemotherapy, one ICI drug with chemotherapy, or two ICI drugs with chemotherapy...Each treatment regimen has its unique safety profile. Early identification and management of ICI-related hematologic toxicities are essential in clinical practice.Systematic Review Registration: PROSPERO CRD42024571508.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal, PD(L)-1 Biomarker, IO biomarker: Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report. (Pubmed Central) - May 13, 2025
To the best of our knowledge, this study represents the first reported case demonstrating the promising efficacy of pyrotinib in HER2-altered NSCLC harboring the ra-re exon 12 R456C mutation. Heterogeneous alterations in the HER2 extracellular segment, such as R456C, may be targetable and could confer survival benefits with HER2-targeted inhibitors.
- || SHR-2010 / Jiangsu Hengrui Pharma
Clinical, P1 data, PK/PD data, Journal: Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study. (Pubmed Central) - May 13, 2025
P1
SHR-2010 was safe and well tolerated after a single dose and exhibited robust blockade of the lectin pathway, supporting further development. The trial is registered at ClinicalTrials.gov (NCT05398510).
- || AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Journal: Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. (Pubmed Central) - May 13, 2025
P3
Adjuvant PD-1 blockade with camrelizumab significantly improved event-free survival with manageable toxicities, highlighting its potential role in the management of locoregionally advanced NPC. ClinicalTrials.gov Identifier: NCT03427827.
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal, Adverse events, PD(L)-1 Biomarker, IO biomarker: Observation on the Therapeutic Efficacy of Camrelizumab Combined with Chemotherapy in Non-small Cell Lung Cancer and the Cutaneous Immune-related Adverse Events: A Retrospective Study. (Pubmed Central) - May 13, 2025
This study supports the utility of cirAEs as biomarkers for predicting the validity of immunotherapy in NSCLC. It proposes a novel, multi-parameter prognostic model to assess patient outcomes more accurately.
- | imrecoxib (BAP 909) / Jiangsu Hengrui Pharma
Journal: Imrecoxib attenuates osteoarthritis by modulating synovial macrophage polarization through inactivating COX-2/PGE2 signaling pathway. (Pubmed Central) - May 13, 2025
Furthermore, Imrecoxib regulates macrophage polarization through the COX-2/PGE2 pathway. This study unravels that Imrecoxib protects joint cartilage and attenuates osteoarthritis by modulating synovial macrophage polarization through inactivating COX-2/PGE2 signaling pathway, providing new drug delivery strategy for the clinical treatment of OA.
- ||| Journal, Adverse events: Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study. (Pubmed Central) - May 13, 2025
Furthermore, higher baseline TSH levels, younger age, and treatment with tislelizumab or camrelizumab were associated with an increased risk of immune-related hypothyroidism, whereas lower baseline TSH levels were linked to a higher risk of immune-related hyperthyroidism. Close clinical and hormonal monitoring is recommended for patients with high-risk factors before and throughout the course of immunotherapy, particularly during the initial 2 to 4 months of PD-1 inhibitor treatment.
- || HRS-1780 / Jiangsu Hengrui Pharma
Clinical, PK/PD data, Journal: Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study. (Pubmed Central) - May 13, 2025
HRS-1780 PK and safety profiles did not differ significantly between healthy and renal impairment subjects. This supports the drug dose regimen for renal impairment patients in clinical practice.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: RAFAS-001: Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - May 13, 2025
P2, N=32, Recruiting, Sponsor: Fujun Zhang
This supports the drug dose regimen for renal impairment patients in clinical practice. Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Jun 2024 --> Dec 2028
- |||||| SHR-A1912 / Jiangsu Hengrui Pharma
Enrollment open: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - May 13, 2025
P3, N=280, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Jun 2024 --> Dec 2028 Not yet recruiting --> Recruiting
- || Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: MA-ASCT-II-002: Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (clinicaltrials.gov) - May 13, 2025
P2, N=120, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Not yet recruiting --> Recruiting Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial completion date, Trial primary completion date: Resilire: Reverse HER2-negative Immune Resistant Breast Cancer (clinicaltrials.gov) - May 12, 2025
P2, N=10, Recruiting, Sponsor: Fudan University
Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Mar 2024 --> Mar 2026 Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Jul 2026 --> Oct 2026
- | AiTan (rivoceranib) / HLB Bio Group
Journal: A gelable polymer loaded with curcumin and apatinib absorbed in gelatin sponge delays postoperative residual tumor growth. (Pubmed Central) - May 12, 2025
Moreover, GS-CT loaded Cur and Apa (GS-CT-CA) delayed postoperative residual tumor growth in intraperitoneal and subcutaneous postoperative mouse models. These findings demonstrated that our gel carrier system significantly prevents postoperative residual tumor growth because of enhanced drug accumulation and sustained drug release at the tumor site.
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer. (Pubmed Central) - May 12, 2025
The study suggests that the integration of PD-1 inhibitors and apatinib in second-line and subsequent therapies demonstrated promising efficacy and acceptable safety in advanced DGC patients. The concentrations of CA125, LDH, and PLTs may serve as prognostic indicators for DGC.
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Enrollment open: Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - May 12, 2025
P=N/A, N=1516, Recruiting, Sponsor: First Hospital of China Medical University
The concentrations of CA125, LDH, and PLTs may serve as prognostic indicators for DGC. Not yet recruiting --> Recruiting
- ||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion: Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. (clinicaltrials.gov) - May 11, 2025
P3, N=131, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker: Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC. (Pubmed Central) - May 11, 2025
P2
Active, not recruiting --> Completed Pre-NAT SUVmax, and ?SUVmax% are promising biomarkers for predicting pathological response to neoadjuvant camrelizumab and chemotherapy.
- | Journal, BRCA Biomarker, PARP Biomarker: Case Report: Two cases of chemotherapy refractory aggressive variant prostate cancer with extreme durable response to PARP inhibitor. (Pubmed Central) - May 9, 2025
These two cases demonstrating a satisfactorily durable response to PARP inhibitors indicating its clinical benefit in AVPC population with detected DNA damage response (DDR) defects. The survival improvement with PARP inhibitors observed in our clinical experiences, along with current advances in tumor sequencing provide more information on future clinical trials and explorations of innovative therapies in AVPC population.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Journal, PARP Biomarker: Response to PARP inhibitor in EGFR-tyrosine kinase inhibitor-resistant metastatic lung adenocarcinoma with germline PALB2 mutation. (Pubmed Central) - May 9, 2025
The treatment achieved surprising results and lasted for more than 4.5 months. Our study provided evidence that metastatic lung adenocarcinoma with germline PALB2 could benefit from PARPi, which improves patient outcomes.
- ||| HS-10370 / Jiangsu Hansoh Pharma
New P1 trial: HS-10370-103: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 9, 2025
P1, N=762, Not yet recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical, Retrospective data, Review, Journal: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis. (Pubmed Central) - May 9, 2025
Dalpiciclib has the best therapeutic effect in PFS. Meanwhile, dalpiciclib has the highest risk of adverse events and the 3/4 adverse events incidence compared with the others.
- || HRS-7535 / Kailera Therapeutics
New P1 trial: Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - May 8, 2025
P1, N=24, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- |||||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis (clinicaltrials.gov) - May 8, 2025
P3, N=380, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Meanwhile, dalpiciclib has the highest risk of adverse events and the 3/4 adverse events incidence compared with the others. Not yet recruiting --> Recruiting
- | Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Journal: Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE. (Pubmed Central) - May 7, 2025
The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.
- | AiTan (rivoceranib) / HLB Bio Group, temozolomide / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Real-world evidence: Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. (Pubmed Central) - May 7, 2025
P2
Overall, 92.4% and 45.2% of the patients experienced any-grade and grade 3-4 TRAEs, respectively. This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability.
- || HRS-7535 / Kailera Therapeutics
Trial completion: A Clinical Study of Mass Balance of [14C]HRS-7535 (clinicaltrials.gov) - May 7, 2025
P1, N=6, Completed, Sponsor: Shandong Suncadia Medicine Co., Ltd.
This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability. Not yet recruiting --> Completed
- | Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Journal: Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE. (Pubmed Central) - May 6, 2025
The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New trial: An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes (clinicaltrials.gov) - May 5, 2025
P=N/A, N=10000, Not yet recruiting, Sponsor: Second Affiliated Hospital of Guangxi Medical University
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310) (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_736;
P3
The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population. These results suggest meaningful clinical benefit of cam + rivo as first-line therapy for uHCC compared to sor regardless of baseline AFP level or etiology.
- Transarterial chemoembolization (TACE) with or without anti-PD1/PD-L1 systemic therapy in unresectable hepatocellular carcinoma: A meta-analysis of randomized clinical trials (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_692;
This meta-analysis demonstrates the significant efficacy of TACE combined with immunotherapy in patients with unresectable HCC. Further data from ongoing studies with extended follow-up are necessary to assess the long-term benefits and safety of this combination approach.
- TAE-HAIC combined with lenvatinib plus camrelizumab or sintilimab plus bevacizumab for unresectable HCC with high tumor burden: a retrospective comparison [WITHDRAWN] (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_411;
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with short-course radiotherapy and CAPOX as total neoadjuvant therapy for pMMR locally advanced rectal cancer: Interim results (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_408;
P2
Further data from ongoing studies with extended follow-up are necessary to assess the long-term benefits and safety of this combination approach. Treatment included SCRT (25 Gy/5 fractions), six cycles of CAPOX (oxaliplatin 130 mg/m2 on day 1; capecitabine 1000 mg/m2 BID on days 1
- AiRuiKa (camrelizumab) / HLB Bio Group
Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Advanced Pancreatic Cancer: A Clinical Trial [WITHDRAWN] (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_407;
- AiRuiKa (camrelizumab) / HLB Bio Group
Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: A pooled analysis of two phase III trials (Foyer) - May 4, 2025 - Abstract #ESMOGI2025ESMO_GI_353;
P3
Its occurrence correlates with improved outcomes, suggesting RCCEP as a potential biomarker for predicting treatment response and survival in advanced ESCC. These findings offer insights for patient management and treatment optimization.
- Itari (linperlisib) / Shanghai YingLi Pharma
LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABLE, MULTI-CENTER PHASE IB/II STUDY (LINCH TRIAL) (Room B) - May 4, 2025 - Abstract #ICML2025ICML_1204;
P1/2
These findings offer insights for patient management and treatment optimization. Preliminary results from LINCH study suggest that linperlisib combined with CHOP as first-line treatment for PTCL achieved promising efficacy and manageable safety, supporting further investigation in larger population.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group, Oncaspar liquid (pegaspargase) / Servier
Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study (Room B) - May 4, 2025 - Abstract #ICML2025ICML_1113;